Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Eur Cytokine Netw ; 19(4): 156-65, 2008 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19103521

RESUMO

The cyclin kinase inhibitor p21WAF1 is expressed in most, if not all, differentiated cells in the human body and represents an important regulator of cell cycle control and terminal differentiation in the monocyte/macrophage lineage. It has been reported in macrophage cell lines that p21WAF1 expression is sensitive to numerous molecules including cytokines, but nothing was known about p21WAF1 regulation in human peripheral blood monocytes in response to Th2 cytokines. We report here, that IL-13 increases p21WAF1 expression in human blood monocytes. This induction is a transcription-dependent event, leading to an increase in mRNA content. We show that the signalling pathway for IL-13-induced p21WAF1 expression may involve the IL-4R alpha and the IL-13R alpha1 chains, and the tyrosine and JAK2 kinases. Also, p21WAF1 plasmid-based gene activation only requires a minimal p21WAF1 promoter, containing a putative PPRE. Since IL-13 signalisation involves PPARgamma, we tested PPARgamma involvement in p21WAF1 gene activation by using metabolic inhibitors of arachidonic acid metabolism, or by restoring PPARgamma expression in a defective cell line. We found that inhibition of PPARgamma increases IL-13-induced p21WAF1 gene expression in these models. These data argue that IL-13 upregulates p21WAF1 expression in monocytes via JAK/STAT pathway, and that the activation of PPARgamma by this cytokine can counteract this induction.


Assuntos
Inibidor de Quinase Dependente de Ciclina p21/metabolismo , Interleucina-13/metabolismo , Monócitos/metabolismo , PPAR gama/metabolismo , Fatores de Transcrição STAT/metabolismo , Células Cultivadas , Inibidor de Quinase Dependente de Ciclina p21/genética , Humanos , Monócitos/efeitos dos fármacos , Prostaglandina D2/análogos & derivados , Prostaglandina D2/biossíntese , Inibidores de Proteínas Quinases/farmacologia , Especificidade por Substrato , Transcrição Gênica/genética , Regulação para Cima
2.
J Immunol ; 180(7): 4939-47, 2008 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-18354219

RESUMO

We recently demonstrated that in vitro peroxisome proliferator-activated receptor-gamma (PPARgamma) activation of mouse peritoneal macrophages by IL-13 or PPARgamma ligands promotes uptake and killing of Candida albicans through mannose receptor overexpression. In this study, we demonstrate that i.p. treatment of immunocompetent and immunodeficient (RAG-2(-/-)) mice with natural and synthetic PPARgamma-specific ligands or with IL-13 decreases C. albicans colonization of the gastrointestinal (GI) tract 8 days following oral infection with the yeast. We also showed that Candida GI infection triggers macrophage recruitment in cecum mucosa. These mucosal macrophages, as well as peritoneal macrophages, overexpress the mannose receptor after IL-13 and rosiglitazone treatments. The treatments promote macrophage activation against C. albicans as suggested by the increased ability of peritoneal macrophages to phagocyte C. albicans and to produce reactive oxygen intermediates after yeast challenge. These effects on C. albicans GI infection and on macrophage activation are suppressed by treatment of mice with GW9662, a selective PPARgamma antagonist, and are reduced in PPARgamma(+/-) mice. Overall, these data demonstrate that IL-13 or PPARgamma ligands attenuate C. albicans infection of the GI tract through PPARgamma activation and hence suggest that PPARgamma ligands may be of therapeutic value in esophageal and GI candidiasis in immunocompromised patients.


Assuntos
Candidíase/imunologia , Candidíase/metabolismo , Proteínas de Ligação a DNA/metabolismo , Gastroenteropatias/metabolismo , Síndromes de Imunodeficiência/metabolismo , Interleucina-13/uso terapêutico , PPAR gama/metabolismo , Animais , Candida albicans/efeitos dos fármacos , Candida albicans/fisiologia , Candidíase/tratamento farmacológico , Candidíase/patologia , Ceco/efeitos dos fármacos , Ceco/metabolismo , Movimento Celular/efeitos dos fármacos , Proteínas de Ligação a DNA/deficiência , Proteínas de Ligação a DNA/genética , Feminino , Gastroenteropatias/tratamento farmacológico , Gastroenteropatias/imunologia , Gastroenteropatias/patologia , Síndromes de Imunodeficiência/tratamento farmacológico , Síndromes de Imunodeficiência/imunologia , Síndromes de Imunodeficiência/patologia , Lectinas Tipo C/metabolismo , Ligantes , Macrófagos/citologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Camundongos , Camundongos Knockout , PPAR gama/antagonistas & inibidores , Receptores de Superfície Celular/metabolismo , Rosiglitazona , Tiazolidinedionas/uso terapêutico
3.
Eur J Immunol ; 37(6): 1642-52, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17458857

RESUMO

The class B scavenger receptor CD36 is a component of the pattern recognition receptors on monocytes that recognizes a variety of molecules. CD36 expression in monocytes depends on exposure to soluble mediators. We demonstrate here that CD36 expression is induced in human monocytes following exposure to IL-13, a Th2 cytokine, via the peroxisome proliferator-activated receptor (PPAR)gamma pathway. Induction of CD36 protein was paralleled by an increase in CD36 mRNA. The PPARgamma pathway was demonstrated using transfection of a PPARgamma expression plasmid into the murine macrophage cell line RAW264.7, expressing very low levels of PPARgamma, and in peritoneal macrophages from PPARgamma-conditional null mice. We also show that CD36 induction by IL-13 via PPARgamma is dependent on phospholipase A2 activation and that IL-13 induces the production of endogenous 15-deoxy-Delta12,14-prostaglandin J2, an endogenous PPARgamma ligand, and its nuclear localization in human monocytes. Finally, we demonstrate that CD36 and PPARgamma are involved in IL-13-mediated phagocytosis of Plasmodium falciparum-parasitized erythrocytes. These results reveal a novel role for PPARgamma in the alternative activation of monocytes by IL-13, suggesting that endogenous PPARgamma ligands, produced by phospholipase A2 activation, could contribute to the biochemical and cellular functions of CD36.


Assuntos
Antígenos CD36/metabolismo , Interleucina-13/farmacologia , Monócitos/metabolismo , PPAR gama/fisiologia , Anilidas/farmacologia , Animais , Ácidos Araquidônicos/farmacologia , Antígenos CD36/genética , Linhagem Celular Tumoral , DNA/metabolismo , Inibidores Enzimáticos/farmacologia , Eritrócitos/efeitos dos fármacos , Eritrócitos/parasitologia , Expressão Gênica/efeitos dos fármacos , Humanos , Hipoglicemiantes/farmacologia , Macrófagos/efeitos dos fármacos , Macrófagos/metabolismo , Macrófagos Peritoneais/efeitos dos fármacos , Macrófagos Peritoneais/metabolismo , Camundongos , Monócitos/efeitos dos fármacos , Organofosfonatos/farmacologia , PPAR gama/agonistas , PPAR gama/antagonistas & inibidores , Fagocitose/efeitos dos fármacos , Fosfolipases A/antagonistas & inibidores , Fosfolipases A2 , Plasmodium falciparum/fisiologia , Prostaglandina D2/análogos & derivados , Prostaglandina D2/metabolismo , Prostaglandina D2/farmacologia , Ligação Proteica/efeitos dos fármacos , Rosiglitazona , Tiazolidinedionas/farmacologia , Transfecção
4.
Histochem Cell Biol ; 123(6): 585-93, 2005 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15959796

RESUMO

We investigated the immunohistochemical distribution of active NF-kappaB p65 and peroxisome proliferator-activated receptor (PPAR) subtypes alpha and gamma in the different phases of liver steatonecrosis and cirrhosis induced in rats after 3 and 9 weeks of carbon tetrachloride (CCl4) intoxication. CCl4 treatment can induce changes in the expression of NF-kappaB and PPARs. Immunohistochemical analysis of liver tissue sections from rats with steatonecrosis or cirrhosis demonstrated a significant increase in the number of NF-kappaB-positive and TNF-alpha-positive hepatocytes and Kupffer cells. In healthy controls, no expression of active NF-kappaB was detected. In previous studies, we have demonstrated that Kupffer cells isolated from rats with CCl4-induced steatonecrosis produced more reactive oxygen intermediates than cells isolated from normal rats. These oxidants could activate NF-kappaB and lead to an overexpression of TNF-alpha, observed in liver tissue sections. After CCl4 ingestion, the rat livers demonstrated a significantly decreased number of hepatocytes expressing PPARalpha and PPARgamma and a significantly increased number of ED2-positive Kupffer cells expressing these transcription factors, compared to normal. The activation of the p65 isoform of NF-kappaB correlates negatively with transcription of the alpha and gamma isoforms of PPAR in hepatocytes, and positively in Kupffer cells. These results suggest that the regulation and the role of these two transcription factors differ in the two cell types studied.


Assuntos
Hepatopatias/metabolismo , Fígado/efeitos dos fármacos , NF-kappa B/análise , Receptores Ativados por Proliferador de Peroxissomo/análise , Animais , Tetracloreto de Carbono/administração & dosagem , Tetracloreto de Carbono/toxicidade , Doença Hepática Induzida por Substâncias e Drogas , Doença Crônica , Hepatócitos/química , Hepatócitos/efeitos dos fármacos , Hepatócitos/patologia , Imuno-Histoquímica , Células de Kupffer/química , Células de Kupffer/efeitos dos fármacos , Células de Kupffer/patologia , Fígado/química , Fígado/patologia , Hepatopatias/patologia , Masculino , PPAR alfa/análise , PPAR gama/análise , Ratos , Ratos Sprague-Dawley , Fator de Necrose Tumoral alfa/análise
5.
Immunity ; 19(3): 329-39, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14499109

RESUMO

Macrophage mannose receptor (MMR) is an important component of the innate immune system implicated in host defense against microbial infections such as candidiasis and in antigen presentation. We demonstrate here that the MMR expression is induced in mouse peritoneal macrophages following exposure to PPARgamma ligands or to interleukine-13 (IL-13) via a PPARgamma signaling pathway. Ligand activation of the PPARgamma in macrophages promotes uptake, killing of Candida albicans, and reactive oxygen intermediates production triggered by the yeasts through MMR overexpression. We also show that MMR induction by IL-13 via PPARgamma is dependent on phopholipase A2 activation and that IL-13 induces 15d-PGJ2 production and nuclear localization. These results reveal a novel signaling pathway controlling the MMR surface expression and suggest that endogenous PPARgamma ligand produced by phospholipase A2 activation may be an important regulator of MMR expression by IL-13.


Assuntos
Interleucina-13/metabolismo , Lectinas Tipo C/genética , Macrófagos/metabolismo , Lectinas de Ligação a Manose/genética , Receptores de Superfície Celular/genética , Receptores Citoplasmáticos e Nucleares/metabolismo , Fatores de Transcrição/metabolismo , Animais , Antígenos de Plaquetas Humanas/imunologia , Candida albicans/imunologia , Candidíase/imunologia , Candidíase/metabolismo , Lectinas Tipo C/metabolismo , Ligantes , Receptor de Manose , Lectinas de Ligação a Manose/metabolismo , Camundongos , Oxidantes/metabolismo , Fagocitose/imunologia , Receptores de Superfície Celular/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...